Optimizing Phase Ib with the right partner.

As clinical development evolves to enhance solutions for sponsors, the demand for hybrid designs in studies requiring early patient data continues to grow. While there are many benefits to running hybrid protocols, there are several challenges that must also be mitigated. A strong partner who understands those challenges can make all the difference in advancing studies safely and with optimal cost and time efficiencies.

Navigate the complexities of Phase Ib with confidence.

By pairing Phase I operational methodology with therapeutic experience and expertise, we de-risk delivery for your Phase Ib studies.

The Fortea approach

Our flexible matrix model adjusts to match your specific study and team's preferences. We offer:

- Lighter-touch, nimble solutions for smaller studies with typical clinical pharmacology endpoints
- Global scalability for larger studies and increased therapeutic area support for more complex indications
- Ability to support secondary/exploratory pharmacodynamic endpoints

Focus on earlier patient access

- Our partnerships optimize alignment for sponsor pipelines, front-loading site identification and vendor qualification
- Proactive site identification and a network of relationships enable us to streamline startup and activation, so your studies start sooner

Fortrea

Experience

Count on our global network of scientists, consultants and specialists in multiple disciplines for deep insights into Phase Ib studies

Process

Benefit from our fit-for-purpose, flexible operational model

Resources

Rely on our scalable, cross-functional expertise to propel your studies forward

Centricity

Experience the difference with a partner that tailors solutions for you and patients

LEARN MORE at fortrea.com

Fortrea